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ABSTRACT
Objectives: Abatacept is the only agent currently
approved to treat rheumatoid arthritis (RA) that targets
the co-stimulatory signal required for full T-cell activation.
No studies have been conducted on its effect on the
synovium, the primary site of pathology. The aim of this
study was to determine the synovial effect of abatacept in
patients with RA and an inadequate response to tumour
necrosis factor alpha (TNFa) blocking therapy.
Methods: This first mechanistic study incorporated both
dynamic contrast-enhanced (DCE) magnetic resonance
imaging (MRI) and arthroscopy-acquired synovial biopsies
before and 16 weeks after therapy, providing tissue for
immunohistochemistry and quantitative real-time PCR
analyses.
Results: Sixteen patients (13 women) were studied; all
had previously failed TNFa-blocking therapy. Fifteen
patients completed the study. Synovial biopsies showed a
small reduction in cellular content, which was significant
only for B cells. The quantitative PCR showed a reduction
in expression for most inflammatory genes (Wald statistic
of p,0.01 indicating a significant treatment effect), with
particular reduction in IFNc of 252% (95% CI 273 to
215, p,0.05); this correlated well with MRI improve-
ments. In addition, favourable changes in the osteopro-
tegerin and receptor activator of nuclear factor kappa B
levels were noted. DCE–MRI showed a reduction of 15–
40% in MRI parameters.
Conclusion: These results indicate that abatacept reduces
the inflammatory status of the synovium without disrupting
cellular homeostasis. The reductions in gene expression
influence bone positively and suggest a basis for the
recently demonstrated radiological improvements that have
been seen with abatacept treatment in patients with RA.
Understanding of disease pathogenesis in rheuma-
toid arthritis (RA) has led to novel approaches in
targeted drug development. Despite the demon-
strated success of tumour necrosis factor (TNF)
antagonists, up to 50% of patients have an
inadequate response to TNF blockade therapy.1–4
This observation has fuelled the search for alter-
native targeted approaches.
Abatacept is a recombinant fusion protein
comprising the extracellular domain of human
cytotoxic T-lymphocyte antigen 4 and a fragment
of the Fc domain of human IgG1. It acts by
competing with CD28 for binding to CD80/CD86,
modulating the second co-stimulatory signal
required for full T-cell activation.5 6
Abatacept has demonstrated benefits in patients
with RA and an inadequate response to metho-
trexate7 that are comparable to those observed in
studies of TNF blockade, with efficacy also
confirmed in the particularly resistant group of
patients who have failed TNF blockade therapy.8
There is limited information on the impact of co-
stimulation modulation on the synovium. The
objective of this first mechanistic study was to
determine the synovial effect of abatacept in a TNF
antagonist-resistant group of patients. A novel and
validated method of gene expression analysis was
employed in combination with immunohisto-
chemistry to evaluate the changes in synovial
pro-inflammatory cytokine gene expression and
cell populations, respectively, with evaluation of
magnetic resonance imaging (MRI) changes before
and after abatacept therapy.
PATIENTS AND METHODS
This was a collaborative, prospective, open-label
study between the Academic Unit of
Musculoskeletal Disease, University of Leeds and
the Center for Innovative Therapy, University of
California San Diego, sponsored by Bristol-Myers
Squibb. Leeds research ethics committee approval
was obtained before study initiation. The study
was conducted in accordance with the ethical
principles of the Declaration of Helsinki. All
patients provided written informed consent. The
US Food and Drug Administration registration
number for this clinical trial is NCT00162201.
Patients
All patients were recruited from the Leeds Biologic
Clinic, had a diagnosis of RA, as defined by the
1987 American College of Rheumatology criteria9
and had currently or previously failed a TNF-
blocking therapy. TNF blockade inefficacy was
defined as failure of the disease activity score 28
(DAS28) to improve by 1.2 or more after 3 months
of therapy as per British Society of Rheumatology
guidelines.10 Patients were also required to have
evidence of active disease defined by a DAS28 of
more than 5.1 and a tender and swollen knee joint
identified as a target joint for arthroscopy.
Exclusion criteria included: patients with evi-
dence of active tuberculosis; previous tuberculosis;
chest x ray granuloma or tuberculosis exposure
with a mantoux reading of 5 mm or greater if no
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previous history of bacillus Calmette–Gue´rin (BCG), or 10 mm
or more if patients had previously received BCG. Pregnant or
lactating women; patients with a history of septic arthritis in
the last year and those with severe co-morbidity, including a
history of recurrent infections, were also excluded.
Concomitant therapy
Background disease-modifying antirheumatic drugs for at least
3 months and at stable doses for at least 28 days before the first
dose of abatacept were required (methotrexate (subcutaneous/
intramuscular), hydroxychloroquine and sulphasalasine per-
mitted). Low-dose stable corticosteroids and/or stable non-
steroidal anti-inflammatory drugs were allowed. Patients who
were currently receiving TNF-blocking agents were required to
have discontinued etanercept and adalimumab for at least
28 days or infliximab for at least 60 days before day 1.
Study schedule
Following successful screening at a maximum of day 228,
patients underwent clinical evaluation to confirm the DAS28
(erythrocyte sedimentation rate; ESR) score and also dynamic
contrast-enhanced (DCE) MRI and arthroscopy of the target
knee joint between days 26 and 0. Arthroscopy was performed
within 2 days of the DCE–MRI scan. All patients received
abatacept by intravenous infusion according to baseline weight
(,60 kg received 500 mg, 60–100 kg inclusive received 750 mg
and .100 kg received 1000 mg). Six infusions were adminis-
tered, each over approximately 30 minutes on days 1, 15, 29, 57,
85 and 113.
Clinical assessments were repeated at day 57. Following
completion of treatment, patients had further clinical evalua-
tion for DAS28 (ESR) calculation, DCE–MRI and arthroscopy of
the target knee joint between days 120 and 127. Below is a
summary of methods (complete details included in the
supplementary information published online only).
Arthroscopy and synovial biopsy
Patients underwent medical arthroscopy of a swollen knee joint
before commencing abatacept therapy and after completion of
treatment as described above with multiple synovial biopsies
obtained. The arthroscopist (RJR) was blinded to the clinical
response.
Immunohistochemistry
The cell types analysed by immunohistochemistry included:
lining layer (LL) and sub-lining layer (SL) CD3+, CD154
(CD40L)+ and CD4+ T cells; CD80+ and CD86+ antigen
presenting cells; CD20+ and CD79+ B cells; CD55+ synovial
fibroblasts; CD54+ cells (intercellular adhesion molecules);
CD68+ synovial macrophages; and CD11b+ neutrophils, macro-
phages and dendritic cells. A standard staining procedure using
ChemMate (DakoCytomation, Glostrup, Denmark) was used.
3,39-Diaminobenzidine was used to develop colour.
Microscopic analysis
Sections were randomly analysed and the histological features
scored in blinded fashion (by MHB and AE) using a validated
semiquantitative scoring system.11
Quantitative real-time PCR
Methods for messenger RNA analysis have previously been
described.12 Pooled biopsy fragments were used to synthesise
complementary DNA. The TaqMan PCR method was under-
taken for gene expression analysis of IL-1, IL-6, matrix
metalloproteinase (MMP) 1, MMP-3 and IFNc. Results were
expressed in relative expression units.12
DCE–MRI and image processing
Dynamic (during and after contrast agent gadolinium diethy-
lenetriaminepentaacetic acid) MRI of the knee was performed
using a Philips 1.5T Gyroscan ACS-NT whole-body scanner
(Philips Medical Systems, Best, The Netherlands) with a Philips
quadrature knee coil.
Image analysis
Commercial software (Analyze, Mayo Clinic, New York, USA)
and software developed in-house13 were used to calculate values
for the maximal enhancement (ME) and the initial rate of
contrast enhancement (IRE) on a pixel-by-pixel basis. ME and
IRE provide an assessment of the synovial microcirculation.
Measurements of MRI parameters
Global
ME and IRE were measured in regions of interest (ROI) defining
the extent of the synovitis using the image analysis software at
a level of 10 pixels below the tibial plateau to the top of the
suprapatellar pouch (SPP) (regions of SPP, cartilage–pannus
junction and a distant site in the SPP).14 Data analysis was
performed by a blinded investigator (LAR).
Statistical analysis
Immunohistochemistry
Median baseline semiquantitative scores for cell populations
were calculated for responders, non-responders and the overall
patient population. The Wilcoxon signed rank test was applied
to determine significant changes in the parameters following
abatacept therapy. As this was a pilot study comprising
relatively small numbers, Bonferroni correction was not applied.
Any significant changes observed posttreatment would repre-
sent trends for potential further evaluation.
Gene expression data
Summary statistics and their mean changes and mean
percentage changes from baseline were provided for mRNA
levels of pro-inflammatory markers for responders, non-respon-
ders and the overall patient population. Mean and mean
Table 1 Baseline patient demographics and disease characteristics
All patients
(n = 16)
Patient demographics
Age, years 53.8 (11.5)
Gender, % female 81.0
Race, % white 94.0
Weight, kg 72.6 (17.3)
Disease characteristics
Rheumatoid factor positive* (%) 75.0
CRP, mg/l 5.8 (5.6)
ESR, mm/h 58.9 (27.0)
VAS, 100 mm 66.5 (15.5)
Baseline DAS28 7.1 (0.9)
Baseline tender joint count, /28 14.0 (6.0)
Baseline swollen joint count, /28 19.2 (7.2)
Data are presented as means (SD) unless otherwise stated; *n = 15; CRP, C-reactive
protein; DAS28, disease activity score 28; ESR, erythrocyte sedimentation rate; VAS,
visual analogue scale for patient global assessment of disease activity.
Extended report
Ann Rheum Dis 2009;68:1220–1227. doi:10.1136/ard.2008.091876 1221
Figure 1 (A) Median change in synovial
expression of cellular infiltrate after
4 months of treatment with abatacept.
Multiple synovial biopsies were obtained
from representative inflamed sites and
stained with antibodies to a range of
synovial markers. Synovial lining layer
(LL) and sub-lining layer (SL) expression
of each marker was scored semi-
quantitatively on a five-point scale (0,
minimal infiltration; 4, maximal
infilatration) and a median percentage
change from baseline calculated.
*p,0.05. Error bars represent 25th and
75th percentiles; the number of patients
analysed was 11 in all cases. (B) Example
of CD68 expression in paired synovial
tissue samples from a patient with
rheumatoid arthritis treated with
abatacept. Panels I and II are the negative
controls for the patient at baseline and
post-abatacept, respectively. Panels III
and IV demonstrate macrophage (CD68)
staining at baseline and post-abatacept,
respectively. Considerable LL and SL
CD68 expression is observed in the
baseline biopsy; expression continues to
be marked post-abatacept. ICAM-1,
intercellular adhesion molecule type 1.
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percentage changes of log-transformed PCR data were expressed
as geometric mean and the geometric mean percentage changes,
respectively. Point estimates and the two-sided 95% CI on the
log scale were exponentiated to obtain estimates on the original
scale.
The treatment effect on all pro-inflammatory gene expression
was tested simultaneously using mean treatment effects and
their covariance matrix in post-hoc analyses based on Wald
statistics; a p value of less than 0.01 indicates a significant
treatment effect on the parameters simultaneously.
Magnetic resonance imaging
Median values of ME and IRE were calculated by dividing the
sum IRE or ME results for each ROI by the number of pixels
enhancing within the ROI. Median values of percentage change
from baseline for ME and IRE were calculated. The post-hoc
Pearson correlation test evaluated for a relationship between the
gene expression data and MRI outcomes.
RESULTS
Baseline patient demographics and disease characteristics
Sixteen patients were recruited (13 female; mean age
53.8 years); 15 completed the study (one patient dropped out
due to elective toe surgery) (table 1). Twelve of the 15 patients
had received more than one TNF-blocking agent, 12 were on
concomitant methotrexate, 75% of patients were rheumatoid
factor positive. Mean baseline DAS28 was 7.1 (SEM 0.22), with
mean swollen and tender joint counts of 14.0 (SD 6.0) and 19.2
(SD 7.2), respectively. High baseline inflammatory markers
were noted with a mean C-reactive protein (CRP) level of
5.8 mg/dl (SD 5.6) and ESR of 58.9 mm/h (SD 27.0).
Clinical response
A gradual (significant) decline in overall DAS28 was recorded,
with mean DAS28 at baseline, day 57 and day 120 of 7.1 (SEM
0.22; n = 16), 6.13 (SEM 0.34; n = 14) and 5.77 (SEM 0.37;
n = 15), respectively (p,0.01). Nine of the 15 patients (60%)
completing the study demonstrated a clinical response to
abatacept treatment (reduction in DAS28 of >1.2). Ten of the
15 patients demonstrated a ‘‘moderate’’ EULAR response; one
patient had a ‘‘good’’ EULAR response. A median (25th, 75th
percentile) percentage reduction in CRP of 66.7% (90.0%,
44.4%) was noted from baseline. No significant differences in
the baseline clinical features were observed between the clinical
response and non-response groups (data not shown).
Immunohistochemistry
Small reductions in some of the synovial markers analysed were
observed following abatacept treatment (fig 1A). A modest but
significant (p,0.05) reduction in SL CD20 was noted from
baseline (0.83) to day 120 (0.42), with a median change (25th,
75th percentile) of 20.4 (20.8, 20.1). A trend for reduction in
the SL baseline and posttreatment values was observed for
CD11b (2.35 and 1.93), CD68 (2.52 and 2.33), CD40 (1.04 and
0.48), CD79 (0.21 and 0.08) and intercellular adhesion molecule
type 1 (3.16 and 2.18). Trends in LL reductions from baseline to
posttreatment, respectively, were also seen for CD68 (3.58 and
3.0) and CD55 (2.93 and 2.28) with a small reduction in LL
Figure 2 Geometric mean percentage
change in synovial gene expression in
patients after 4 months of treatment with
abatacept in (A) all patients combined
(n = 14{), (B) disease activity score 28
(DAS28) responders (n = 8{) versus
DAS28 non-responders (n = 6{). RNA
was isolated from the synovium using
chloroform extraction and reverse
transcribed to cDNA. mRNA levels of
tumour necrosis factor alpha (TNFa), IL-
1b, IL-6, matrix metalloprotease (MMP)
1, MMP-3, IFNc, receptor activator of
nuclear factor kappa B (RANK), RANK
ligand (RANKL) and osteoprotegerin
(OPG) were quantified using TaqMan
quantitative PCR analysis. Data are
expressed as the geometric mean
percentage change in gene expression
relative to baseline. Error bars represent
95% CI. *95% CI do not include zero.
{Two patients (one responder and one
non-responder) had IFNc levels below the
detectable limit at baseline and one
patient (non-responder) had IL-6 levels
below the detectable limit at baseline;
these patients were excluded from
analysis for these cytokines. Wald
statistics indicate a significant treatment
effect of abatacept on IFNc, IL-1b, IL-6,
MMP-1 and MMP-3 simultaneously
(p,0.01).
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depth from 1.45 to 0.96 (fig 1A), although these changes were
highly variable. Figure 1B shows CD68 expression in represen-
tative paired synovial tissue samples, in which the degree of
expression is largely unchanged following abatacept treatment.
Gene expression analysis
In the total population, a significant (p,0.05) geometric mean
percentage change in IFNc gene expression of 252% (95% CI
273 to 215) was observed (fig 2A). In addition, reductions
(non-significant) in IL-1b, IL-6, MMP-1, MMP-3 and TNFa gene
expression were noted. Interestingly, a decreasing trend in
receptor activator of nuclear factor kappa B (RANK) and RANK
ligand (RANKL) gene expression was seen in association with
an increase in osteoprotegerin gene expression (fig 2A).
The mean treatment effects of IFNc, IL-1b, IL-6, MMP-1 and
MMP-3 (20.32,20.27,20.23,20.62 and20.67, respectively) and
their covariance matrix were estimated. Using Wald statistics, a
value of p,0.01 was noted, indicating a significant treatment
effect of abatacept on these parameters simultaneously.
Analysis of the responder (reduction in DAS28 score of >1.2;
n = 7) and non-responder groups demonstrated significant
reductions (p,0.05) in IFNc gene expression in the responder
group only, with a mean percentage change of 269% (95% CI
287 to 227) (fig 2B). Significant reductions (p,0.05) in
additional parameters were also observed, namely mean
percentage change in gene expression of IL-1b (253%; 95% CI
277 to 26), MMP-1 (261%; 95% CI 283 to 211) and MMP-3
(259%; 95% CI 282 to 25) (fig 2B). In addition, osteoprote-
gerin expression increased posttreatment (geometric percentage
mean change of 53% in responders).
Immunohistochemistry demonstration of reduced synovial B-
cell expression was confirmed by a reduction in CD19 transcript
levels (data not shown) although IgM transcript levels were
unchanged.
Magnetic resonance imaging
For the total population, a significant median percentage
reduction from baseline in ME-global of 228.5% (p = 0.001)
was observed with a reduction also in the IRE-global of234.9%.
Eleven of 15 patients (73.3%) showed a reduction in IRE-global
and 14 of 15 patients (93.3%) in ME-global pre to posttreat-
ment, indicating a reduction in synovitis. There was a greater
reduction in IRE-global in clinical responders compared with
non-responders (median percentage change 242% and 210%,
respectively); however, there was no significant difference in
changes in ME-global between clinical responders and non-
responders. The data for the smaller ROI were more variable
and no consistent changes were observed across the whole
study population. Figure 3 presents the median percentage
change from baseline in key MRI measures for the total
population. Results include DCE–MRI parameters within the
global region as well as ROI at the CPJ and the SPP. Figure 4
shows representative example of a DCE–MRI image with the
area used to compute global IRE and ME and images showing
changes in DCE–MRI pre and post-abatacept treatment.
Pearson correlation analyses were undertaken to evaluate for a
relationship between the gene expression data and MRI
outcomes. A good correlation between IFNc and IRE-global,
as well as ME-global, was observed (fig 5; r = 0.628 and
0.7863).
DISCUSSION
Abatacept, a modulator of T-cell co-stimulation, has demon-
strated efficacy and an acceptable safety profile in patients with
RA and an inadequate response to methotrexate7 and in the
challenging group of patients resistant to TNF blockade.8 Little
Figure 3 Median percentage change in key magnetic resonance
imaging (MRI) measures. MRI of the knee was performed, and measures
of the initial rate of enhancement (IRE) and maximal enhancement (ME)
made in the global region as well as in regions of interest (ROI) at the
cartilage–pannus junction (CPJ) and the suprapatellar pouch (SSP).
Values for the ME and IRE are calculated from the sum of the enhancing
pixels in each region of interest, expressed as arbitrary units. Error bars
represent 25th and 75th percentiles.
Figure 4 Five characteristic dynamic gadolinium-enhanced magnetic
resonance imaging sagittal scans acquired from the knee with
superimposed colour data showing values of initial rate of enhancement
(IRE) across synovial space following gadolinium enhancement—pixels
shown in yellow represent high IRE values whereas red show relatively
lower values. Image (A) shows global region of interest outlined in white,
which defines the extent of the synovitis at a level of 10 pixels below the
tibial plateau to the top of the suprapatellar pouch, avoiding
enhancement from muscle and arteries in each of the five sagittal
images. Images (B) and (C) are an example of pre and posttreatment,
respectively.
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information is available on the changes that occur with
abatacept on the synovium, the primary site of disease. This
study is the first to evaluate the mechanistic effects of
abatacept, with particular focus on TNF blockade failures.
The findings demonstrate contrasting synovial changes: a clear
generalised reduction in synovial pro-inflammatory gene expres-
sion (particularly IFNc), but with little change in the composi-
tion of the synovial infiltrate. In particular, the reduction in
synovial IFNc is consistent with a T-cell-dependent mechanism
of action. The improvement observed in imaging outcomes with
reduced tissue perfusion and vascular permeability (indicative of
inflammation and correlated with synovial volume)15 comple-
ments these findings further.
Improved understanding of T-cell biology, with recognition
of antigen-independent T-cell influences strongly supports the
involvement of T cells in RA pathogenesis.16 17 The relative
inefficacy of T-cell depletion strategies led to the concept of
modulating as opposed to depleting T-cell function, with the
targeting of one of the more prominent T-cell co-stimulatory
signals, the CD28:CD80/CD86, by interaction with abatacept.
This hypothesis-generating study specifically concentrated on
patients failing one or more TNF antagonists. Several studies to
date have utilised synovial immunohistochemistry to evaluate
the effects of therapeutic intervention.11 18–20 In this collabora-
tive study, we chose to complement this technique with a
validated method of real-time quantitative PCR utilising pooled
biopsy fragments for gene expression analysis. DCE–MRI was
included to correlate the clinical and synovial data with refined
synovial imaging.
Sixty per cent of patients treated with abatacept demon-
strated a significant improvement in disease activity (DAS28
reduction of >1.2). Although the DAS28 remained high,
suggesting only a modest clinical improvement, these data are
consistent with a resistant cohort and mimic the published trial
data that formed the basis for the approval of abatacept and
rituximab in TNF blockade failures.8 21
Several key points can be learned from this study. Only a
modest reduction in cellular infiltrate composition was observed
with abatacept, and surprisingly this was found mainly in the
B-cell population; this is in marked contrast to similar studies
conducted to assess the effect of TNF blockade, which revealed
significant reductions in cellularity (including macrophage
populations).11 18–20 The modest clinical improvement could
account for these findings; however, this difference is not
necessarily a surprise when one considers the nature of the
targets. TNFa is a pleiotropic cytokine, the effects of which
include promoting the recruitment of inflammatory infiltrate
and the induction of adhesion molecules. Conversely, abatacept
does not directly target the T cell; by targeting the more classic
co-stimulatory signal, selective modulation of T-cell activation
occurs. Notably, there was no significant decrease in the
number of SL macrophages even though others have proposed
CD68+ cell depletion as a primary biomarker predictive of
clinical response.22 We would suggest the importance of
considering novel mechanisms of action despite the findings
contrasting with previously held assumptions. Semiquantitative
as opposed to quantitative analysis could be argued also to
account for the relative negative findings, although previous
studies have demonstrated the ability of this method to
demonstrate significant changes after effective treatment.11 23–26
In addition, the significant reduction in CD20 in the responder
group suggests the sensitivity of the method.
This observed reduction in CD20+ cells also suggests more of
a modulating as opposed to cellular-depleting effect of
abatacept; In fact, human cytotoxic T-lymphocyte antigen
type 4 immunoglobulin binds CD80/CD86 on B cells,27 as well
as T cells. Further detailed studies are required to explore this
observation, including an evaluation of synovial germinal centre
formation and other markers of B-cell biology.
In contrast to the histology, the gene expression study
demonstrated diminution in pro-inflammatory gene expression,
with significant reductions in MMP-1 and MMP-3, and smaller
reductions in TNFa, IL-1b and IL-6. This is consistent with a
previous study that also illustrated a reduction in MMP gene
expression following effective treatment.28 MMP expression,
being an ‘‘integration’’ of all of the pro-inflammatory signals,
would explain the more pronounced reduction in MMP gene
expression compared with the individual cytokines. These
findings are emphasised with a demonstration of treatment
effect on pro-inflammatory gene expression simultaneously
(Wald statistic). The significant reduction in IFNc gene
expression, however, certainly suggests an effective functional
effect of T-cell modulation on the synovium. Although
comprising small numbers, comparison of the abatacept
response and non-response groups further verifies this observa-
tion, with significant reductions in MMP-1, MMP-3 and IL-1b
gene expression, in addition to IFNc gene expression noted in
the response group. A reduction in CD19 transcript levels was
consistent with the immunohistochemistry findings; interest-
ingly, IgM transcripts did not change, suggesting the B-cell
Figure 5 The relationship between the IFNc gene expression and
magnetic resonance imaging (MRI) outcomes. Pearson correlation
analyses were carried out to evaluate the relationship between gene
expression data and MRI outcomes. A good correlation between IFNc
and the initial rate of enhancement (IRE)-global, as well as maximal
enhancement (ME)-global was observed.
Extended report
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effect is different to that noted with anti-CD20 both in
magnitude and character.29
Another interesting finding from this study was the divergent
(and advantageous) trend observed between RANK/RANKL
and osteoprotegerin gene expression. Osteoprotegerin inhibits
the effects of the RANK/RANKL interaction by competing with
RANK, thereby functioning as a soluble decoy receptor for
RANKL. The reduction in RANK/RANKL expression with
concomitant osteoprotegerin upregulation is consistent with a
more regulatory influence on osteoclast cell differentiation and
bone resorption. Whereas the exact mechanism underlying this
observation is unclear, it correlates well with the radiological
improvement that has been reported with abatacept therapy.7
DCE–MRI was undertaken pre and post-abatacept therapy,
with measurement of rates of contrast enhancement (IRE and
ME, shown to correlate with inflammatory activity and blood
vessel density)15 confirming a general reduction in the IRE and
ME values of all regions evaluated, with a significant reduction
in ME-global. The inability to detect a significant reduction in
the global IRE and lack of consistent change in the small ROI is
likely to reflect the relatively small sample size, response
heterogeneity and/or reproducibility of DCE–MRI measure-
ments. In addition, the differences between responders and non-
responders make it harder to detect a reduction in the group as a
whole. Nevertheless, the correlation between the MRI para-
meters and IFNc gene expression further suggests the synovium
as a site of action for abatacept.
Several limitations must also be considered in the interpreta-
tion of these data. First, as a result of ethical considerations we
did not include a placebo arm. Second, the study population
was small and comprised patients with severe disease who were
refractive to previous treatment; other similar studies in this
population have shown limited changes and a large variation in
responses.29 30 Finally, it is possible that the primary impact of
abatacept may be at another site, such as secondary lymphoid
organs.
In summary, we report the first mechanistic study incorpor-
ating DCE–MRI and tissue for immunohistochemistry and
quantitative real-time PCR analyses before and after abatacept
therapy. These results demonstrate a treatment effect on
inflammatory mediators simultaneously, with convincing effect
on IFNc, confirming a functional T-cell effect. This contrasts
with a modest histological change, suggesting deactivation
rather than depopulation of the synovium, although a reduction
in synovial ‘‘quantity’’ is observed as evidenced by the MRI.
Finally, this reduction in inflammation correlates well with the
effect on IFNc. Overall, the study findings are in keeping with
the immunomodulatory nature of selective co-stimulation. The
changes in bone biology and B cells add an interesting
dimension to the potential effect and mechanism of action of
co-stimulation modulation. Further lines of investigation in a
larger patient population should further elucidate the synovial
effects of co-stimulation modulation with abatacept.
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